10-QPeriod: Q1 FY2006

QUEST DIAGNOSTICS INC Quarterly Report for Q1 Ended Mar 31, 2006

Filed April 28, 2006For Securities:DGX

Summary

Quest Diagnostics Inc. reported strong financial performance for the first quarter ended March 31, 2006, with a significant increase in net revenues and net income compared to the same period in 2005. This growth was primarily driven by organic revenue growth in its core clinical laboratory testing business and the strategic acquisition of LabOne, Inc. The company also demonstrated improved operating efficiencies, partly due to ongoing Six Sigma and standardization initiatives. Despite facing integration costs related to the LabOne acquisition and charges associated with consolidating operations, Quest Diagnostics maintained a healthy increase in profitability and a strong cash flow from operations. Key financial metrics highlight the company's robust performance. Net revenues rose by 17.9%, with the LabOne acquisition contributing substantially. Diluted earnings per share saw a notable increase, reflecting higher net income. The company also continues to return value to shareholders through dividends and a significant share repurchase program. Management's outlook suggests confidence in future growth, supported by ongoing operational improvements and strategic investments.

Key Highlights

  • 1Net revenues increased by 17.9% to $1.56 billion for the first quarter of 2006 compared to the prior year period, driven by organic growth and the acquisition of LabOne.
  • 2Net income grew to $144.6 million ($0.72 per diluted share) from $131.6 million ($0.64 per diluted share) in the first quarter of 2005.
  • 3The acquisition of LabOne, Inc. contributed significantly to revenue growth, accounting for approximately 10.2% of the consolidated revenue increase.
  • 4Operating income was $244.5 million, representing 15.7% of net revenues, despite incurring $26.8 million in special charges related to integration activities.
  • 5Cash flow from operating activities significantly improved, reaching $240.7 million in the first quarter of 2006, up from $136.0 million in the prior year period.
  • 6The company repurchased approximately 2.0 million shares of common stock for $104 million during the quarter, as part of an ongoing share repurchase program with $618 million remaining authorization.
  • 7Quest Diagnostics adopted SFAS 123R effective January 1, 2006, resulting in $19.4 million of stock-based compensation expense recognized in the first quarter of 2006.

Frequently Asked Questions

Revenue growth was driven by two primary factors: organic growth in the core clinical laboratory testing business, which saw a 13.4% increase and a 8.7% rise in testing volume, and the strategic acquisition of LabOne, Inc. which closed in November 2005 and contributed approximately 10.2% to consolidated revenue growth.

Quest Diagnostics adopted SFAS 123R effective January 1, 2006. This resulted in the recognition of $19.4 million in stock-based compensation expense in the first quarter of 2006, which negatively impacted operating income and net income per share. This adoption does not require restatement of prior periods.

The LabOne acquisition has been accretive to revenue and is expected to yield approximately $40 million in annual synergies by the end of 2007. However, the company incurred $23.3 million in integration costs during the first quarter of 2006, primarily for employee severance, which impacted operating results. The purchase price allocation for LabOne was still in progress as of the filing date.

Quest Diagnostics decided to discontinue operations of its test kit manufacturing subsidiary, NID, on April 19, 2006, due to ongoing quality issues and product holds. This decision is expected to result in a pre-tax charge of up to $45 million in the second quarter of 2006, mainly related to asset write-offs and liabilities.